EXACT Sciences Co. (NASDAQ:EXAS) – Dougherty & Co issued their FY2019 EPS estimates for shares of EXACT Sciences in a research note issued on Monday, December 16th, according to Zacks Investment Research. Dougherty & Co analyst K. Bauser expects that the medical research company will earn ($1.59) per share for the year. Dougherty & Co has a “Buy” rating and a $120.00 price objective on the stock. Dougherty & Co also issued estimates for EXACT Sciences’ Q4 2019 earnings at ($0.33) EPS and FY2020 earnings at ($0.33) EPS.
Several other equities analysts have also issued reports on the company. Stifel Nicolaus began coverage on EXACT Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $110.00 price objective for the company. Jefferies Financial Group decreased their price objective on EXACT Sciences from $138.00 to $120.00 and set a “buy” rating for the company in a research report on Wednesday, October 30th. Leerink Swann decreased their price objective on EXACT Sciences from $133.00 to $105.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. BidaskClub upgraded EXACT Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, December 18th. Finally, William Blair reiterated a “buy” rating on shares of EXACT Sciences in a research report on Tuesday, September 10th. Two investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $122.40.
Shares of EXAS stock traded up $3.10 on Wednesday, reaching $95.58. The company had a trading volume of 1,518,312 shares, compared to its average volume of 1,743,787. The company has a current ratio of 2.75, a quick ratio of 2.63 and a debt-to-equity ratio of 0.67. The company has a 50-day moving average of $87.02 and a 200-day moving average of $102.10. EXACT Sciences has a 12 month low of $60.95 and a 12 month high of $123.99. The stock has a market cap of $12.01 billion, a PE ratio of -70.28 and a beta of 1.32.
EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Tuesday, October 29th. The medical research company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.10. The company had revenue of $218.81 million during the quarter, compared to analysts’ expectations of $216.14 million. EXACT Sciences had a negative return on equity of 29.06% and a negative net margin of 29.83%. EXACT Sciences’s revenue was up 85.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.37) EPS.
A number of large investors have recently added to or reduced their stakes in the business. Jennison Associates LLC boosted its holdings in shares of EXACT Sciences by 216.9% in the 2nd quarter. Jennison Associates LLC now owns 3,303,930 shares of the medical research company’s stock valued at $389,996,000 after buying an additional 2,261,394 shares during the last quarter. Nuveen Asset Management LLC acquired a new stake in shares of EXACT Sciences in the 2nd quarter valued at approximately $122,065,000. Vanguard Group Inc. boosted its holdings in shares of EXACT Sciences by 2.8% in the 2nd quarter. Vanguard Group Inc. now owns 11,521,644 shares of the medical research company’s stock valued at $1,360,016,000 after buying an additional 309,043 shares during the last quarter. Westfield Capital Management Co. LP boosted its holdings in shares of EXACT Sciences by 4,595.5% in the 2nd quarter. Westfield Capital Management Co. LP now owns 281,730 shares of the medical research company’s stock valued at $33,255,000 after buying an additional 275,730 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of EXACT Sciences by 210.3% in the 2nd quarter. Renaissance Technologies LLC now owns 391,560 shares of the medical research company’s stock valued at $46,220,000 after buying an additional 265,360 shares during the last quarter. 86.59% of the stock is owned by hedge funds and other institutional investors.
In other EXACT Sciences news, insider G Bradley Cole sold 28,016 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $80.38, for a total transaction of $2,251,926.08. Following the completion of the transaction, the insider now owns 30,987 shares of the company’s stock, valued at approximately $2,490,735.06. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 2.20% of the company’s stock.
EXACT Sciences Company Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.